Ticker brief
REGN REGENERON PHARMACEUTICALS
Consumer, Non-cyclical · Biotechnology
last close
$794.19
1 day
-1.7%
14 days
-1.2%
mkt cap
$68.6B
signals 14d
30
authors 14d
24
crowd 14d
+0.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 29% cheap · 4 pctile own 1y | IV/HV 1.01× (as of 2026-08-06) |
| Skew — 25Δ RR 30d | -0.036 33 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.39 normal | 5-session Δ +0.06 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2025-09-25 (z=3.1) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now +0.10 (−1 bearish … +1 bullish)
Who spoke24
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @harry03994688 | A | -0.79 | 3 | +0.60 |
| @nataninvesting | B | -1.17 | 2 | +0.65 |
| @fwpharma | B | +0.98 | 2 | +0.05 |
| @BiopharmIQ | B | · | 2 | +0.50 |
| @SixSigmaCapital | B | -0.40 | 2 | +0.45 |
| @AktienTrader1 | C | -0.14 | 1 | +0.45 |
| @MartyChargin | C | -0.27 | 1 | +0.35 |
| @bioinvestor24 | A | -0.45 | 1 | +0.15 |
| @DivIncomeBcast | C | +0.27 | 1 | +0.45 |
| @OracleNYSE | C | -0.08 | 1 | +0.50 |
| @PeloSwing | C | -0.75 | 1 | +0.50 |
| @adamfeuerstein | A | +1.41 | 1 | +0.50 |
| @PrismMarketView | C | · | 1 | +0.50 |
| @SayNoToTrading | A | -0.52 | 1 | -0.65 |
| @afortunetrading | C | -1.44 | 1 | +0.25 |
| @ShakePryzby1 | B | +0.06 | 1 | +0.15 |
| @TheNewMoney_app | C | · | 1 | +0.25 |
| @mathlonning | A | -0.77 | 1 | +0.65 |
| @HeidingOut | C | -1.40 | 1 | +0.40 |
| @shanaka86 | A | +1.96 | 1 | +0.35 |
| @EmmanuelInvest | C | -1.11 | 1 | +0.10 |
| @MorningstarInc | B | +0.80 | 1 | -0.40 |
| @TalkMarkets | C | · | 1 | +0.00 |
| @Globalmess65 | C | -1.00 | 1 | +0.20 |
Recent signals30of 30 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @Globalmess65 | +0.20 | Praises RVMD's launch and compares its rise with successful biotech precedents. | — | tweet ↗ |
| 2026-08-28 | @TalkMarkets | +0.00 | Frames a valuation and growth-efficiency divergence between VRTX and REGN. | — | tweet ↗ |
| 2026-08-27 | @harry03994688 | +0.50 | Advocates rotating from priced-in hardware toward software and AI-enabled biotechnology. | -1.7% | tweet ↗ |
| 2026-08-26 | @harry03994688 | +0.55 | Author compares biotech platforms and argues ABCL could join REGN and ALNY above a 50% approval-success potential. | -2.5% | tweet ↗ |
| 2026-08-25 | @MorningstarInc | -0.40 | Morningstar analysts now rate VRTX and REGN as expensive and newly overvalued. | -4.7% | tweet ↗ |
| 2026-08-25 | @nataninvesting | +0.50 | Discloses long positions in four healthcare names and a thesis that select medtech stocks remain attractively priced. | -4.7% | tweet ↗ |
| 2026-08-25 | @EmmanuelInvest | +0.10 | Regeneron committed to deploy Veeva Vault CRM globally. | -4.7% | tweet ↗ |
| 2026-08-24 | @shanaka86 | +0.35 | Explains FDA approval of Pasatru while highlighting uncertainty omitted from conference and PR claims. | -4.1% | tweet ↗ |
| 2026-08-23 | @HeidingOut | +0.40 | Presents a sustained bullish thesis for biotech and health-tech dips, led by XBI. | -4.8% | tweet ↗ |
| 2026-08-23 | @SixSigmaCapital | +0.50 | Recaps completed REGN and BRKR trades with entry and exit prices. | -4.8% | tweet ↗ |
| 2026-08-23 | @SixSigmaCapital | +0.40 | Reviews a past healthcare basket, including TWST gains and a realized 50% NTLA loss. | -4.8% | tweet ↗ |
| 2026-08-22 | @mathlonning | +0.65 | REGN's rising Dupixent and Eylea HD advertising suggests it is time to act. — The phrase 'It's time' conveys forward bullish intent based on rising advertising. | -4.8% | tweet ↗ |
| 2026-08-21 | @TheNewMoney_app | +0.25 | Reports $341,250 of REGN 1040 calls purchased for the June 2027 expiry. | -4.8% | tweet ↗ |
| 2026-08-21 | @ShakePryzby1 | +0.15 | Sees a potential biotech leadership cycle and highlights CRSP as a breakout candidate. | -4.8% | tweet ↗ |
| 2026-08-21 | @afortunetrading | +0.25 | Highlights renewed movement in healthcare and crypto-linked stocks. | -4.8% | tweet ↗ |
| 2026-08-20 | @BiopharmIQ | +0.50 | FDA approved REGN's Pasatru for adults with FOP after Phase 3 data showed roughly 90%-94% lesion reduction. | -3.9% | tweet ↗ |
| 2026-08-20 | @BiopharmIQ | +0.50 | Biotech opening roundup lists FDA, clinical-data, approval and offering catalysts with associated price moves. | -3.9% | tweet ↗ |
| 2026-08-20 | @SayNoToTrading | -0.65 | Cut REGN position from 100 shares to 50 shares. — Explicitly halves a REGN holding due to persistent performance drag and weak long-term growth. | -3.9% | tweet ↗ |
| 2026-08-20 | @harry03994688 | +0.75 | Presents REGN and ABCL as defensible antibody-discovery platforms in an emerging digital-biology cycle. | -3.9% | tweet ↗ |
| 2026-08-19 | @PrismMarketView | +0.50 | Reports FDA approval of a Regeneron treatment for a rare bone disease. | -5.5% | tweet ↗ |
| 2026-08-19 | @fwpharma | +0.50 | Reports US approval of Regeneron's Pasatru as the second approved FOP drug. | -5.5% | tweet ↗ |
| 2026-08-19 | @adamfeuerstein | +0.50 | FDA approved a Regeneron drug for a disease causing dangerous bone growth. | -5.5% | tweet ↗ |
| 2026-08-19 | @PeloSwing | +0.50 | Reports FDA approval of a second treatment for fibrodysplasia ossificans progressiva | -5.5% | tweet ↗ |
| 2026-08-19 | @OracleNYSE | +0.50 | Reports FDA approval of a second treatment for fibrodysplasia ossificans progressiva. | -5.5% | tweet ↗ |
| 2026-08-18 | @DivIncomeBcast | +0.45 | Shares Grok's decade-long sector picks; ticker cap retains the first two baskets. | -2.0% | tweet ↗ |
| 2026-08-17 | @fwpharma | -0.40 | Regeneron stopped a uveitis study after an unfavorable benefit-risk assessment. | -1.5% | tweet ↗ |
| 2026-08-17 | @nataninvesting | +0.80 | Valuation model estimates $1,060 one-year REGN target and 31% upside. | -1.5% | tweet ↗ |
| 2026-08-16 | @bioinvestor24 | +0.15 | Questions KYMR's valuation, differentiation and development timeline while comparing peers and FOMO. | -1.2% | tweet ↗ |
| 2026-08-16 | @MartyChargin | +0.35 | Expresses positive sentiment toward a basket of drug stocks. | -1.2% | tweet ↗ |
| 2026-08-15 | @AktienTrader1 | +0.45 | Trade REGN despite its volatility. — Explicitly states an intention to trade REGN while acknowledging biotech volatility. | -1.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.